Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
NT$10 receipts win NT$10 million prizes
10/05/2026 09:02 PM - Politics
OCAC minister, family accused of misusing public resources overseas
10/05/2026 08:58 PM - Politics
New Eswatini envoy pledges support for Taiwan's int'l participation
10/05/2026 08:17 PM - Politics
Taichung mayoral rivals Ho, Chiang visit transport project sites
10/05/2026 07:41 PM - Society
6 Taipei police officers disciplined over misconduct in gay bar raid
10/05/2026 07:04 PM